Thomas Cueni is Director General of IFPMA, the global association of pharmaceutical research companies, based in Geneva, and Secretary of the Global Biopharmaceutical CEO Roundtable (BCR). In this capacity, Thomas Cueni was instrumental in creating the AMR Action Fund, a collective venture launched in July 2020 to bridge the current gap in funding for the development of new antibiotics. Thomas Cueni represents the innovative biopharmaceutical industry on the ACT Accelerator, the Access to COVID-19 Tools (ACT) Accelerator, a unique global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines. Thomas Cueni is Chair of the Business Committee at the OECD Health Committee and also serves on the Board of Directors of the City Cancer Challenge (CCan), an initiative aiming to improve cancer care in major cities in low- and middle-income countries. Cueni also serves as industry co-chair of the APEC Biopharmaceutical WG on Ethics. Furthermore, he is Chair of the Board of the cross-sectoral AMR Industry Alliance, a group committed to tackling the threat of antimicrobial resistance that includes more than 100 companies and associations representing Rx pharma, generics, biotech, and diagnostics. Prior to joining IFPMA, he was Secretary General of Interpharma, the association of pharmaceutical research companies in Switzerland, and for many years was a member of the Board and Chair of a key committee of the EFPIA. Prior to his appointment with Interpharma, Thomas Cueni had a career as a journalist, inter alia as a London correspondent for the “Basler Zeitung” and “Der Bund”, and he served as a Swiss career diplomat with postings in Paris (OECD) and Vienna (IAEA, UNIDO). He studied at the University of Basel, the London School of Economics, and the Geneva Graduate Institute for International Studies and has Master’s degrees in economics (University of Basel) and politics (London School of Economics).